Transaction DateRecipientSharesTypePriceValue
1st October 2020Stephen P Macmillan498Grant/award etc.$0.00
22nd September 2020Karleen Marie Oberton5,461Exercise of derivative$26.21$143,132.81
21st September 2020Karleen Marie Oberton15,000Open or private sale$62.50$937,500.00
21st September 2020Karleen Marie Oberton15,000Exercise of derivative$26.21$393,150.00
3rd September 2020Amy Mc Bride Wendell2,591Grant/award etc.$11.75$30,444.25
3rd August 2020Benjamin Jordan Cohn2,617Open or private sale$71.23$186,408.91
3rd August 2020Benjamin Jordan Cohn1,938Open or private sale$71.27$138,121.26
3rd August 2020Benjamin Jordan Cohn2,986Exercise of derivative$23.82$71,126.52
3rd August 2020Benjamin Jordan Cohn369Open or private sale$71.22$26,280.18
21st July 2020Charles J Dockendorff1,983Grant/award etc.$0.00
Hologic logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986.

Ticker: HOLX
Sector: Healthcare
Industry: Medical Instruments & Supplies
SEC Central Index Key (CIK): 859737
Employees: 6478
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $744 M (0%)
Inventory, Net: $414 M (0%)
Assets, Current: $2 B (10%)
Property, Plant and Equipment, Net: $456 M (0%)
Other Assets, Noncurrent: $519 M (235%)
Assets: $7 B (0%)
Long-term Debt, Current Maturities: $566 M (0%)
Accounts Payable, Current: $127 M (-31%)
Accrued Liabilities, Current: $476 M (10%)
Liabilities, Current: $1 B (25%)
Long-term Debt, Excluding Current Maturities: $3 B (0%)
Other Liabilities, Noncurrent: $223 M (37%)
Common Stock, Value, Issued: $3 M (0%)
Common Stock, Shares, Issued: $295 Th (0%)
Retained Earnings (Accumulated Deficit): $2 B (-23%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $62 M (46%)
Treasury Stock, Value: $15 Th (59%)
Treasury Stock, Shares: $359 Th (45%)
Stockholders' Equity (Parent): $2 B (6%)
Liabilities and Equity: $7 B (5%)
Cost of Revenue: $225 M (-67%)
Gross Margin: $466 M (-64%)
Research and Development: $55 M (-66%)
Sales and Marketing: $104 M (-71%)
General and Administrative Expenses: $105 M (-59%)
Restructuring Charges: $1 M (-79%)
Operating Income/Loss: $191 M (0%)
Income before taxes: $168 M (-56%)
Provision for income taxes: $32 M (-86%)
EPS (basic): $0.53 (-77%)
EPS (diluted): $0.53 (-77%)